1Kuerer HM,Newman LA,Smith TL,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
2Chollet P,Amat S,Cure H,et al.Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J].Br J Cancer,2002,86(7)1041-1046.
3Sahoo S,Lester SC.Pathology of breast carcinomas after neoadjuvant chemotherapy:an overview with recommendations on specimen processing and reporting[J].Arch Pathol Lab Med,2009,133(4):633-642.
4Pinder SE,Provenzano E,Earl H,et al.Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy[J].Histopathology,2007,50(4):409-417.
5Rabban J.The new edition(7th)AJCC staging system for breast cancer.A summary of key changes[EB/OL],(2010-06)[2015-02-09].http://labmed.ucsf.edu/uploads/210/101_new_ajcc_ staging_of_breast_cancer_what_has_changed.pdf.
6Edge S,Byrd D,Compton C,et al.AJCC cancer staging manual[M].New York:Springer,2010.
7Schnitt SJ,Collins LC.Biopsy interpretation of the breast[M].Philadelphia:Lippincott Williams & Wilkins,2009:435-439.
8Lakhani SR,Ellis 10,Schnitt SJ,et al.WHO classification of tumours of the breast[M].Lyon:IARC Press,2012.
9Rabban JT,Glidden D,Kwan ML,et al.Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy:an unusual and adverse pattern of residual disease[J].Am J Surg Pathol,2009,33(2):256-263.
10Mazouni C,Peintinger F,Wan-Kau S,et al.Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome[J].J Clin Oncol,2007,25(19):2650-2655.
